Creative Biolabs, a premier global contract research organization (CRO), has expanded its robust portfolio of Experimental Autoimmune Encephalomyelitis (EAE) models.
— As the global pharmaceutical industry accelerates the development of targeted therapeutics for autoimmune neurological diseases, identifying the most predictive preclinical models remains a critical translational bottleneck. Addressing this challenge, Creative Biolabs has expanded its robust portfolio of experimental autoimmune encephalomyelitis (EAE) models. Designed to mirror the highly heterogeneous pathology of human multiple sclerosis (MS), these advanced in vivo platforms empower drug developers to rigorously evaluate the efficacy, safety, and mechanism of action for next-generation immunomodulators, biologic agents, and small-molecule drugs.
High-Fidelity EAE Models for Precision Efficacy Evaluation
Human MS encompasses various clinical phenotypes, necessitating distinct antigen-induced models to ensure accurate preclinical data generation. Creative Biolabs provides highly characterized protocols tailored to specific therapeutic targets:
Chronic and Monophasic Modeling: The MOG35-55 induced EAE mice model is widely recognized as a replicable and reliable platform for evaluating compounds targeting T-cell functions. By immunizing C57BL/6 mice with MOG35-55 peptide suspended in complete Freund’s adjuvant (CFA), researchers can induce chronic neuroinflammation characterized by multifocal mononuclear infiltration. It serves as an ideal system for testing drugs requiring sustained pharmacological intervention.
Relapsing-Remitting MS (RRMS) Simulation: For developers focused on the most prevalent form of human MS, the PLP-induced EAE mouse model established in SJL strain mice offers unparalleled translational value. Following targeted immunization and Pertussis Toxin (PT) administration to compromise the blood-brain barrier, this model generates a CD4+ T cell-mediated relapsing-remitting disease course. It provides a unique analytical window to assess both preventive measures and curative interventions across distinct waves of paralysis.
Acute CNS Inflammation: In contrast, the MBP-induced EAE rat model, utilizing susceptible Lewis rats, is heavily utilized for evaluating rapid-onset therapeutics. This model triggers severe, acute central nervous system (CNS) inflammation and sudden paralysis with minimal demyelination, making it highly effective for screening acute anti-inflammatory agents.
Expert Perspectives on Preclinical Model Selection
“The ultimate clinical success of any MS drug candidate relies heavily on the fidelity of the preclinical data generated during the IND-enabling phase,” stated the Scientific Director of Neuroimmunology at Creative Biolabs. “By offering a diversified and meticulously characterized suite of EAE models, we ensure our global biotech partners can perfectly align their candidate’s mechanism of action—whether it involves remyelination, T-cell modulation, or acute inflammation suppression—with the most appropriate immunological pathways and genetic backgrounds.”
Technical Insights: Bridging the Translational Gap in MS Research
A frequently asked question among neuro-researchers is how to accurately quantify therapeutic efficacy and complex physiological changes across varied EAE models. Creative Biolabs resolves this through a multi-parametric assessment framework. Beyond standard daily clinical EAE scoring and body weight monitoring, the company’s pharmacodynamics pipeline integrates high-resolution biomarker analysis, cytokine profiling, pharmacokinetic (PK) sampling, and comprehensive immunohistochemical evaluation of demyelination and focal cellular infiltration.
Accelerate Your Therapeutic Pipeline
Discover how customized in vivo modeling can de-risk your preclinical neuroimmunology portfolio. To explore detailed model specifications, request customized project protocols, or access specialized autoimmune disease services, please visit Creative Biolabs today.
Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Website: https://www.creative-biolabs.com/drug-discovery/therapeutics/
Release ID: 89194920
If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). We will respond and rectify the situation in the next 8 hours.